News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522
Collage photo of Elisa Agostinetto and Marleen Kok
Jul 26, 2024, 00:03

Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522

Elisa Agostinetto shared on X:

“Out in JCO a must-read by Marleen Kok on the limitations of KEYNOTE-522.

To control (financial) toxicity, agencies must limit trial designs where the relative contribution of each phase of treatment (pre vs. postop) cannot be established.”

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer published in JCO

Autors: Marleen Kok, Robbert-Jan Gielen,  Sylvia Adams, Jochen K. Lennerz, Priyanka Sharma, Sibylle Loibl, Erin Reardon, Gabe Sonke, Sabine Linn, Suzette Delaloge, Denis Lacombe, Tim Robinson, Sunil Badve, Miguel Martin, Justin M. Balko, Michail Ignatiadis, Giuseppe Curigliano, Antonio C. Wolff, Elizabeth A. Mittendorf, Sherene Loi, Lajos Pusztai, Sara M. Tolaney, and Roberto Salgado

Must-read by

Source: Elisa Agostinetto/X

Elisa Agostinetto is a Clinical Research Fellow at the Institute Jules Bordet in Brussels, Belgium. She is also a Resident in Medical Oncology at Humanitas Research Hospital in Milan, Italy. Agostinetto specializes in Breast Cancer and Immuno-Oncology.

Antonio C. Wolff Denis Lacombe Elisa Agostinetto Elizabeth A. Mittendorf Erin Reardon Gabe Sonke Giuseppe Curigliano JCO Jochen K. Lennerz Justin M. Balko KEYNOTE-522 Lajos Pusztai Marleen Kok Michail ignatiadis Miguel Martin Priyanka Sharma Robbert-Jan Gielen Roberto Salgado Sabine Linn Sara M. Tolaney Sherene Loi Sibylle Loibl Sunil Badve Suzette Delaloge Sylvia Adams Tim Robinson
Special Coverage
Blog
Dec 22, 2024, 04:24
Jordan Rathkopf: As 2024 winds down, we’ve been reflecting on what a year it’s been
Insight
Dec 22, 2024, 00:21
Eric J. Small: ASCO/Conquer Cancer Foundation Felix Feng Prostate Cancer YIA is now fully endowed
Blog
Dec 21, 2024, 22:40
50 Years of History, a Future to Write Together - AIEOP
Science
Dec 21, 2024, 22:37
Breaking Down the Impact of Ionizing Radiation on Cancer
Blog
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Blog
Dec 21, 2024, 22:33
ABIM will develop two new assessment options focusing on breast cancer and hematologic neoplasms
Blog
Dec 21, 2024, 22:28
Adekemi Oyewusi: EDUCARE - Supporting the medical treatment and education of those impacted by childhood cancer
Blog
Dec 21, 2024, 22:26
Anas Younes: Transforming outcomes for people living with Blood Cancer
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025